Reduces elevated intraocular pressure (IOP). ANDA 203172, held by Sandoz. Brimonidine Tartrate.
As of Nov 16, 2026, ANDA 203172 (Brimonidine Tartrate), held by Sandoz, was first approved by FDA on Mar 4, 2024, with 0 approved supplements and 0 published complete response letters.
Brimonidine tartrate ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 4, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Brimonidine Tartrate0.1% · solution/drops;ophthalmic | Brimonidine Tartrate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters